Cellebrite DI Target of Unusually Large Options Trading (NASDAQ:CLBT)

Posted by George Bondi on Aug 13th, 2026

Cellebrite DI Ltd. (NASDAQ:CLBT – Get Free Report) was the target of some unusual options trading activity on Thursday. Investors acquired 19,988 call options on the company. This represents an increase of 3,311% compared to the typical daily volume of 586 call options.

Cellebrite DI Stock Down 31.2%

Shares of NASDAQ:CLBT traded down $4.76 during mid-day trading on Thursday, reaching $10.48. 14,342,864 shares of the stock were exchanged, compared to its average volume of 1,935,842. The stock’s 50 day simple moving average is $14.59 and its 200-day simple moving average is $14.09. Cellebrite DI has a one year low of $9.58 and a one year high of $19.98. The company has a market cap of $2.62 billion, a P/E ratio of 37.55, a P/E/G ratio of 1.99 and a beta of 1.18.

Insider Activity at Cellebrite DI

In related news, CRO Marcus Jewell sold 12,658 shares of Cellebrite DI stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $12.77, for a total transaction of $161,642.66. Following the transaction, the executive owned 440,101 shares of the company’s stock, valued at $5,620,089.77. This trade represents a 2.80% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Thomas E. Hogan sold 103,188 shares of the business’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $15.76, for a total transaction of $1,626,242.88. Following the transaction, the chief executive officer owned 590,777 shares of the company’s stock, valued at approximately $9,310,645.52. This represents a 14.87% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 157,810 shares of company stock worth $2,475,185 in the last ninety days. Company insiders own 5.70% of the company’s stock.

Institutional Trading of Cellebrite DI

Several institutional investors and hedge funds have recently bought and sold shares of CLBT. Roubaix Capital LLC increased its position in Cellebrite DI by 108.1% during the first quarter. Roubaix Capital LLC now owns 303,215 shares of the company’s stock worth $4,178,000 after buying an additional 157,536 shares during the last quarter. Lazard Asset Management LLC bought a new position in Cellebrite DI during the first quarter worth $2,134,000. Principal Financial Group Inc. increased its holdings in shares of Cellebrite DI by 33.9% in the first quarter. Principal Financial Group Inc. now owns 2,156,166 shares of the company’s stock valued at $29,712,000 after purchasing an additional 545,334 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. increased its holdings in shares of Cellebrite DI by 28.6% in the fourth quarter. Migdal Insurance & Financial Holdings Ltd. now owns 1,350,000 shares of the company’s stock valued at $24,341,000 after purchasing an additional 300,000 shares during the last quarter. Finally, Renaissance Technologies LLC raised its position in shares of Cellebrite DI by 14.7% in the first quarter. Renaissance Technologies LLC now owns 2,860,639 shares of the company’s stock valued at $39,420,000 after purchasing an additional 365,700 shares during the period. Institutional investors own 45.88% of the company’s stock.

Analysts Set New Price Targets

CLBT has been the subject of several recent analyst reports. DA Davidson increased their price target on Cellebrite DI from $20.00 to $22.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Weiss Ratings upgraded Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, May 18th. Finally, Needham & Company LLC decreased their price objective on Cellebrite DI from $18.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, May 15th. Five analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $21.80.

Get Our Latest Stock Analysis on CLBT

Cellebrite DI Company Profile

(Get Free Report)

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.